Vol. 4 No. 2 (2026), Articles
Vol. 4 No. 2 (2026)

ANALYSIS OF MORPHOLOGICAL FEATURES AND PROGNOSTIC VALUE OF INTRATUMORAL STROMAL MAST CELLS IN RENAL CELL CARCINOMA

Articles
Published 2026-02-28
Murod Matyakubovich Atakhonov
Urgench State Medical Institute Assistant Professor, Department of Military Field Surgery, Traumatology and Orthopedics
PDF
DOI

Keywords

renal cell carcinoma, tumor microenvironment, stromal mast cells, prognosis.

How to Cite

ANALYSIS OF MORPHOLOGICAL FEATURES AND PROGNOSTIC VALUE OF INTRATUMORAL STROMAL MAST CELLS IN RENAL CELL CARCINOMA. (2026). Yangi O’zbekistonda Tabiiy Va Ijtimoiy-Gumanitar Fanlar Respublika Ilmiy Amaliy Konferensiyasi, 4(2), 149-154. https://universalpublishings.com/index.php/gumanitar/article/view/16941
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The prognostic relevance of intratumoral stromal mast cells (MCs) in renal cell carcinoma (RCC) remains insufficiently investigated and controversial. The present study aimed to evaluate the quantitative characteristics of stromal mast cells in RCC and to analyze their relationship with major clinical, anatomical, and histopathological prognostic factors.

PDF
DOI

References

1. Aleksandrov N. S. et al. Use of Raman fluorescence spectroscopy for the diagnosis of clear cell renal cell carcinoma //Clinical and Experimental Morphology. – 2017. – No. 4. – Pp. 59-65.

2. Aleksandrov Nikolai Sergeevich Comparative Immunomorphological and Spectroscopic Characteristics of Kidney Tumors: Author's abstract. Dissertation... Candidate of Medical Sciences. Moscow, 2019. 24 pp.

3. Alyaev Yu. G. et al. Features of the diagnosis of kidney neoplasms up to 4 cm //Medical imaging. – 2003. – No. 2. – P. 33-38.

4. Alyasova A. V. et al. Matrix RNAs of the fcgr3a and fcgr3b genes as monitoring markers for the course of clear cell renal cell carcinoma (pilot study) //Modern technologies in medicine. – 2022. – Vol. 14. – No. 3. – P. 22-27.

5. Anikanova E. V. et al. IGG4-associated ureteral disease //Experimental and Clinical Urology. – 2021. – No. 4. – P. 56-62.

6. Anoyko E. A., Guzeeva E. A. The significance of morphological and immunohistochemical studies in the diagnosis of kidney tumors //Bulletin of Medical Internet Conferences. – Science and Innovation Limited Liability Company, 2013. – Vol. 3. – No. 2. – P. 263-264.

7. Apolikh O. I. et al. Cryoablation of localized renal cancer in a group of patients at high surgical risk //Experimental and Clinical Urology. – 2014. – No. 3. – P. 32-35.

8. Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. //Cancer Treat Rev. 2018;70:127–137.

9. Baek J, Jang NR, Shim YR, Gu MJ. ATRX protein is a potential prognostic marker in clear cell renal cell carcinoma.// Indian J Pathol Microbiol. 2022 Jul-Sep;65(3):598-603

10. Barata P.C., Rini B.I. Treatment of renal cell carcinoma: current status and future directions. //CA Cancer J Clin 2017; 67(6): 507-524.

11. Bazzocchi MV, Zilioli C, Gallone VI, Commisso C, Bertolotti L, Pagnini F, Ziglioli F, Maestroni U, Aliprandi A, Buti S, Procopio G, Ascenti G, Martini C, De Filippo M. The Role of CT Imaging in Characterization of Small Renal Masses. //Diagnostics (Basel). 2023 Jan 17;13(3):334.

12. Bhatnagar N., Ahmad F., Hong H.S., Eberhard J., Lu I.N., Ballmaier M., Schmidt R.E., Jacobs R., Meyer-Olson D. FcyRNI (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcyRII (CD32). //Eur J Immunol 2014; 44(11): 3368-3379.

13. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. //Eur Urol. 2019;75(1):74–84.

14. Chen T, Peng Y, Lei T, Wu C, Wang H, Shi Y. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations. //Pathol Oncol Res.- 2023 Feb 1;29: